



Article

Discordance to ASHP Therapeutic Guidelines Increases the Risk of Surgical Site Infection

Fauna Herawati ^{1,2,*}, Rika Yulia ¹, Heru Wiyono ³, Firdaus Kabiru Massey ¹, Nurlina Muliani ¹, Kevin Kantono ⁴, Diantha Soemantri ⁵ and Retnosari Andrajati ²

¹ Department of Clinical and Community Pharmacy, Faculty of Pharmacy, Universitas Surabaya, Surabaya 60293, Indonesia; rika_y@staff.ubaya.ac.id (R.Y.); firdaus.kabiru@gmail.com (F.K.M.); nurlinamuliani95@gmail.com (N.M.)

² Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia; retnosaria@gmail.com

³ Faculty of Medicine, Universitas Surabaya, Surabaya 60293, Indonesia; herwyno@yahoo.com

⁴ Department of Food Science, Auckland University of Technology, Private Bag 92006, Auckland 1142, New Zealand; kevin.kantono@aut.ac.nz

⁵ Department of Medical Education, Faculty of Medicine, Universitas Indonesia, Depok 16424, Indonesia; diantha.soemantri@ui.ac.id

* Correspondence: fauna@staff.ubaya.ac.id

Citation: Herawati, F.; Yulia, R.; Wiyono, H.; Massey, F.K.; Muliani, N.; Kantono, K.; Soemantri, D.; Andrajati, R. Discordance to ASHP Therapeutic Guidelines Increases the Risk of Surgical Site Infection. *Pharmaceuticals* **2021**, *14*, 1088. <https://doi.org/10.3390/ph14111088>

Academic Editors: Marco Fiore

Received: 16 September 2021

Accepted: 22 October 2021

Published: 27 October 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

Abstract: Clean surgery without contamination does not require prophylactic antibiotics, but there are high-risk surgical procedures that may cause infection and/or involve vital organs such as the heart, brain, and lungs, and these indeed require the use of antibiotics. This study aimed to determine the quantity of antibiotic use based on the defined daily dose (DDD) per 100 bed days and the quality of antibiotic use based on the percentage of concordance with The American Society of Health-System Pharmacists (ASHP) therapeutic guidelines (i.e., route of administration, time of administration, selection, dose, and duration). This includes the profiles of surgical site infection (SSI) in surgical patients from January through June 2019. The study subjects were 487 surgical patients from two hospitals who met the inclusion criteria. There were 322 patients out of 487 patients who had a clean surgical procedure. Ceftriaxone (J01DD04) was the most used antibiotic, with a total DDD/100 bed days value in hospitals A and B, respectively: pre-surgery: 14.71, 77.65, during surgery: 22.57, 87.31, and postsurgery: 38.34, 93.65. In addition, 35% of antibiotics were given more than 120 min before incision. The lowest concordance to ASHP therapeutic guideline in hospital A (17.6%) and B (1.9%) was antibiotic selection. Two patients experienced SSI with bacterial growths of *Proteus* spp., *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *Escherichia coli*. The usage of prophylactic antibiotics for surgical procedures was high and varied between hospitals. Hospital B had significantly lower concordance to antibiotic therapeutic guidelines, resulting to a higher infection rate, compared with hospital A. ASHP adherence components were then further investigated, after which antibiotic dosing interval and injection time was found to be a significant predictor for positive bacterial growth based on logit–logistic regression. Further interventions and strategies to implement antibiotic stewardship is needed to improve antibiotic prescriptions and their use.

Keywords: defined daily dose; surgical site infection; antibiotic stewardship; hospital

1. Introduction

Antimicrobial resistance threatens global health; antibiotic use in surgical specialties is an infection control indicator and may reflect the incidence of surgical site infection. In most developing countries, particularly Indonesia, antibiotics are given before the incision but also during the time from admission to discharge from the hospital which may result in higher chances of antimicrobial resistance. A new strategy is therefore needed to overcome this problem.

Surgery is a medical procedure in the form of an incision made by a surgeon with the aim of preventing or treating an illness. In general, all surgical procedures can pose a risk of infection. Thus, antibiotic prophylaxis is needed to prevent postoperative infection. However, not all types of surgery require antibiotic prophylaxis. Clean surgery without contamination does not require prophylactic antibiotics unless there are high-risk procedures that may cause infection and/or involve vital organs such as the heart, brain, and lungs. Prophylactic antibiotics are generally recommended in some clean and all contaminated operations [1]. In general, the use of antibiotic prophylaxis must be in accordance with therapeutic standards. However, the percentage compliance with guidelines for antibiotic use (e.g., NICE Guidelines, Stanford Health Care Guidelines, Surgical Antimicrobial Prophylaxis Guidelines) is relatively low (under 50%) in several countries such as Qatar (46.5%), Pakistan (< 50%), Italy (40%), and the Philippines (13%) [2].

The mismatch of antibiotic use with therapeutic guidelines is reported to be high in surgical ward [3], ICU [3,4], and medical ward [3] with mismatches to the indication, antibiotic selection [3,4], and time/dose/route/duration of antibiotic administration. Often, differences existed from the internal guidelines [3] especially in prescribing prophylactic antibiotics pre- and postsurgery. A study showed that in pre-surgery, 46% incorrect timing, 32% incorrect dosages, and 20% overly broad antibiotic spectrum were reported; while in postsurgery, they found 74% incorrect duration of antibiotic administration, 29% incorrect dosage or frequency, and 6% overly broad spectrum of antibiotics [5].

Prescribing antibiotics preoperatively can reduce the occurrence of wound infection. Whereas not following the guidelines, for example, by using different spectrum antibiotics or different tissue antibiotic concentrations at the start and during surgery, can reduce antibiotics' effectiveness. Moreover, antibiotic selection pressure leads to antibiotic resistance. The incidence of SSI is significantly higher when prophylactic antibiotics are given postsurgery than when given presurgery with an odds ratio (OR) of 1.89 (95% CI 1.05–3.4). Prophylactic antibiotics more than 120 min preincision showed a higher prevalence of SSI than those within 120 min (OR 5.26; 95% CI (3.29–8.39)) [6–8]. The use of prophylactic antibiotics that are irrational or not in accordance with therapeutic guidelines requires preventive efforts so as not to cause cases of resistance to prophylactic antibiotics. According to the Indonesian National Action Plan for Antimicrobial Resistance 2017–2019, one of the preventive efforts that can be conducted is to evaluate the use of prophylactic antibiotics in its quantity and quality.

World Health Organization (2019) states that implementing antimicrobial stewardship by evaluating the use of antibiotics can optimize the use of antibiotics, encourage behavior change in prescribing antibiotics, improve quality of care and patient outcomes, save unnecessary health care costs, and reduce the emergence, selection, and further spread of antimicrobial resistance (AMR) [9–14]. A systematic review by Nathwani et al. (2019) of 146 studies in North America (49%), Europe (25%), Asia (14%), Africa (3%), South America (3%), and Australia (3%) reported a decrease in length of stay (LOS) and antibiotic expenditure, respectively, by 85 and 92%; mean cost savings in the US study were USD 732 per patient (range: USD 2.50 to 2640), with a similar trend shown in European studies [14]. Hence, taking into account the importance and positive outcome of antibiotics stewardship, this study aimed to evaluate the quantity (DDD/100 bed-days) and quality of prophylactic antibiotic use in surgical patients in hospitals while assessing the impact of concordance towards ASHP therapeutic guideline towards the risk of SSI.

2. Materials and Methods

2.1. Study Design

A retrospective observational study in both hospitals was conducted by observing patients who underwent surgical procedures during hospitalization at a private hospital in Surabaya (hospital A) and West Nusa Tenggara (hospital B) in the period January–June 2019. Hospital A is a private hospital with 235 beds, whereas hospital B is a government

hospital with 411 beds. Both hospitals are referral hospitals. Surgical procedures classifications were (1) clean surgery—surgery performed on an area without preoperative infection and without opening the tract (respiratory, gastrointestinal, urinary, biliary), planned surgery, or primary skin closure with or without the use of closed drains, (2) clean-contaminated operations—operations performed on the ducts (gastrointestinal, biliary, urinary, respiratory, and reproductive except ovaries) or operations without significant contamination, and (3) contaminated surgery—surgery that opened the digestive tract, bile duct, urinary tract, airway to the oropharynx, or reproductive tract except for ovaries with gross spillage [6].

Inclusion criteria included patients aged >18 years old who received prophylactic antibiotics, underwent surgery, and hospitalization in the surgical ward, including surgical wound control within <90 days postoperatively. The exclusion patient criteria were patients in the intensive care unit (ICU), patients who had an infection before surgery, those discharged “against medical advice” (AMA), and those who died.

Slovin’s formula was used to calculate the appropriate sample size (n) from a population using the known population size (N) and the acceptable error value (e). In this study, simple random sampling was used from the population of admitted patients in the study period; N = 267 participants, e = 0.05; therefore, n = 160 participants hospital A; N = 1597 participants, e = 0.05; therefore, n = 320 participants hospital B.

Slovin calculations used Equation (1) as follows:

$$n = \frac{N}{(1 + N \times 0.05^2)} \quad (1)$$

Antibiotic usage data were obtained from patient medical records and antibiotic use records compiled by pharmaceutical software, which stores all patient data. Data were collected from inpatient medical records, including diagnosis, surgery, length of hospitalization, drug name, dose, and the number of antibiotics received. The dataset was anonymized prior to analysis.

In Indonesia, antibiotics can be prescribed to the patient at admission, during patient care, until the patient’s discharge, and usually two weeks after discharge (next outpatient consultation). In this study, antibiotic use classifications were pre-, during, and postsurgery. Presurgery represents antibiotics given before the day of surgery; antibiotics during surgery are given on the day of surgery (120 min preincision to < 24 h after surgery), and antibiotics postsurgery are given > 24 h after surgery.

The obtained data were evaluated for antibiotic uses quantitatively and qualitatively. The quantitative evaluation used DDD per 100 bed-days, while the qualitative analysis was the percentage of antibiotic concordance to the American Society of Health-System Pharmacists (ASHP) Therapy Guidelines in (1) route of administration, (2) time, (3) type, (4) dosage, and (5) duration.

Data on bacterial culture test results were obtained from clinical pathology laboratories, and prevention and control committees of infection to follow up regarding the bacteria that cause SSI in postsurgical patients. Patients with SSI were observed in the time they were in the hospital, and when they went to the doctor for review, until the patient was declared cured.

2.2. Statistical Analysis

All patient data were anonymized prior to analysis. Data analysis was performed descriptively in the form of an analysis of the quantity of prophylactic antibiotic use with the DDD/100 bed-days, which was calculated using the following formula:

$$\frac{\text{DDD}}{100} \text{ bed - days} = \frac{\text{Total Antibiotics (g)} \times 100}{\text{DDD WHO (g)} \times \text{LOS}} \quad (2)$$

where DDD WHO = defined daily dose determined by WHO; LOS = total length of stay.

The percentage of compliance with guidelines of antibiotic use with the ASHP therapeutic guidelines was analyzed using the 2014 SIGN criteria as a quality analysis, including the sensitivity profile of the bacteria causing SSI.

A generalized ANOVA model was also carried out on the aggregated DDD dataset to identify the overall difference between the two hospitals in this study. Z-test, in conjunction with Monte Carlo simulation, was also used to investigate which hospital was most adhering to ASHP guidelines. In addition, logit–logistic regression was utilized in this study to further investigate which ASHP adherence components that would be the significant predictor for reported infection cases. Participants' demographics (e.g., age, gender), comorbidities, and antibiotic usage were included as covariates in the model.

3. Results

A total of 487 patients in both hospitals met the inclusion and exclusion criteria. Table 1 describes the demographic information of the patients in the study. Table 1 shows that 268 patients (55%) were female, 298 patients (61%) were aged between 31 and 60 years old, 393 patients (81%) of patients with out-of-pocket payment, and 57 patients (12%) had comorbidities. Overall, 322 patients underwent surgery with a clean operation category (94 patients in hospital A, and 228 patients in hospital B) (Table 1); in 164 patients (34%), the injection time given was greater than 120 min (Table 2).

Table 1. Demographics information.

Characteristic	Hospital A (N = 164)	Hospital B (N = 323)	Total (N = 487)
Age (years)			
18–30	30 (18.3%)	59 (18.3%)	89 (18.3%)
31–45	56 (34.1%)	95 (29.4%)	151 (31.0%)
46–60	44 (26.8%)	103 (31.9%)	147 (30.2%)
61–75	31 (18.9%)	66 (20.4%)	97 (19.9%)
>75	3 (1.8%)	0	3 (0.6%)
Gender			
Male	61 (37.2%)	158 (48.9%)	219 (45.0%)
Female	103 (62.8%)	165 (51.1%)	268 (55.0%)
Pay providers			
Out of pocket	85 (51.8%)	308 (95.4%)	393 (80.7%)
National Health Insurance	79 (48.2%)	15 (4.6%)	94 (19.3%)
Comorbidities			
Without comorbidities	117 (71.3%)	313 (96.9%)	430 (88.3%)
With comorbidities *	47 (28.7%)	10 (3.1%)	57 (11.7%)
Surgical procedure			
Clean	94 (57.3%)	228 (70.6%)	322 (66.1%)
Clean contaminated	65 (39.6%)	95 (29.4%)	160 (32.9%)
Contaminated **	5 (3.0%)	0	5 (1.0%)

* Comorbidities: diabetes mellitus (DM), hypertension, cardiovascular disease (CVD), gout, cerebrovascular accident (CVA), and others. ** contaminated: an acute incision, nonpurulent drainage.

Table 2. Antibiotic usage for both hospitals.

Category	Hospital A (N = 164)	Hospital B (N = 323)	Total (N = 487)
The number item of antibiotic			
No antibiotic	15 (9.1%)	0	15 (3.1%)
1 antibiotic	130 (79.3%)	323 (100%)	453 (93.0%)
2 antibiotics	18 (11.0%)	0	18 (3.7%)
>2 antibiotics	1 (0.6%)	0	1 (0.2%)
Injection time given			
0–30 min	35 (21.3%)	57 (17.6%)	92 (18.9%)

31–60 min	32 (19.5%)	83 (25.7%)	115 (23.6%)
61–120 min	55 (33.5%)	46 (14.2%)	101 (20.7%)
>120 min	27 (16.5%)	137 (42.4%)	164 (33.7%)
Record not available	15 (9.1%)	0	15 (3.1%)

3.1. Quantity Profile of Prophylactic Antibiotics

Pre-, During, and Postsurgeries

Based on the recapitulation of antibiotic prophylaxis (DDD/100 bed-days) in hospitals A and B, respectively, between January and June 2019, the antibiotic use prophylaxis presurgery was 44.26 and 133.58; during surgery was 33.32 and 132.4; postsurgery was 66.65 and 148.68. Ceftriaxone had the highest DDD/100 patient days in the pre-, during, and postsurgery, with sequences of 14.71 and 77.65, 22.57 and 87.31, 38.34, and 93.65 (Table 3). Overall, hospital B had significantly higher usage than hospital A ($F_{(1,5)} = 66.124$, $p < 0.001$).

Table 3. The DDD per 100 bed-days antibiotics use for surgical procedures.

ATC * Code	Antibiotic Name	Pre-		During		Post-	
		Hospital A	Hospital B	Hospital A	Hospital B	Hospital A	Hospital B
J01CA04	Amoxicillin	-	7.93	-	-	0.72	1.11
J01CR01	Bactesyn ^a	-	-	-	5.59	-	-
J01CR02	Clanexi ^b	-	-	-	-	-	0.54
J01DB04	Cefazolin	0.74	-	2.82	-	1.55	-
J01DB05	Cefadroxil	-	0.94	-	-	-	1.09
J01DD01	Cefotaxime	-	6.07	0.04	8.92	0.04	8.70
J01DD02	Ceftazidime	-	2.87	0.14	3.96	-	3.72
J01DD04	Ceftriaxone	14.71	77.65	22.57	87.31	38.34	93.65
J01DD08	Cefixime	-	18.70	-	-	-	26.79
J01DD62	Cefoperazone Sulbactam	12.26	0.67	3.06	0.62	10.17	0.79
J01DE01	Cefepime	1.47	-	0.14	-	1.45	-
J01DH02	Meropenem	14.34	-	1.59	-	4.94	-
J01FF01	Clindamycin	-	-	-	-	-	1.65
J01GB03	Gentamicin	-	-	-	-	0.17	-
J01MA02	Ciprofloxacin	-	-	-	-	-	1.97
J01MA12	Levofloxacin	-	16.07	0.14	-	0.64	-
J01MA14	Moxifloxacin	-	-	-	23.51	-	3.03
J01XA01	Vancomycin	-	2.68	-	1.60	-	3.41
J01XD01	Metronidazole	0.74	-	2.82	0.89	8.63	2.23
Total		44.26	133.58	33.32	132.40	66.65	148.68

* Anatomical therapeutic chemical; ^a—ampicillin and beta-lactamase inhibitor; ^b—amoxicillin and beta-lactamase inhibitor.

3.2. Quality Profiles of Prophylactic Antibiotics

Other than the route of administration, compatibility with ASHP guidelines was less than 50%. Order from highest to lowest conformity, the concordance to the ASHP guidelines was route of administration, injection given time, dosage, dosing interval, and selection (Table 4). In general, hospital A was more compliant than hospital B. Logistic regression revealed that injection given time ($X^2_{(1,162)} = 283.62$; $p < 0.001$) and dosing interval ($X^2_{(1,162)} = 4.165$; $p < 0.041$) were significant predictors for infection cases in hospital B.

Table 4. The percentage concordance to ASHP Therapeutic Guidelines.

Concordance Type	Hospital A	Hospital B	z-Test (Monte Carlo)
Antibiotic route of administration	96.6	100.0	$z = -0.034; p < 0.05$
Antibiotic injection given time	53.4	42.7	$z = 2.211; p < 0.05$
Antibiotic selection	17.6	1.9	$z = 4.966; p < 0.001$
Antibiotic dosage	16.4	46.7	$z = -7.445; p < 0.001$
Antibiotic dosing interval	19.1	19.2	$z = 0.000; p = 1.0$

3.3. Profile of Surgical Site Infection (SSI)

Surgical site infection occurs related to surgical incision procedures within 90 days of follow-up. Only two patients experienced SSI in this study. Both patients experiencing postoperative SSI were identified after undergoing a third review in the first patient, and after the first review in the second patient. The results of the first patient's pus culture showed the presence of *Proteus* spp. and *S. aureus*, while the second patient had *E. coli* and *S. epidermidis*. Profiles of the types of bacteria that cause SSI are shown in Table 5. Both SSI patients were known to have had a history of diabetes mellitus, with a random blood sugar level of < 200 mg/dL while in the hospital, LOS preoperatively for >1 day, undergoing surgery with a duration of operation > 60 min. The first SSI patient did not receive presurgical antibiotics, while the second patient received 2 × 1 g of ceftriaxone preoperative antibiotics for 1 day. Both SSI patients received the same prophylactic antibiotic, i.e., ceftriaxone 2 × 1 g with the administration time > 120 min, and both dosages were continued until 4–5 days after incision. Neither received antibiotics when they were discharged.

Table 5. The incidence of surgical site infection.

Category	Hospital A	Hospital B
Patients who return for control and culture	0	4
Patients with positive bacteria culture result	0	2
The bacteria culture result	-	Patient 1: <i>Proteus</i> sp. dan <i>S. aureus</i> Patient 2: <i>E. coli</i> dan <i>S. epidermidis</i>

3.4. Bacteria Sensitivity Profile Causes SSI

The results of antibiotic sensitivity tests showed that *Escherichia coli* bacteria are still sensitive to several types of antibiotics, such as cefoxitin, chloramphenicol, fosfomycin, oxacillin, tetracycline, and vancomycin. Bacteria *Proteus* spp. were sensitive to antibiotics such as amoxicillin, amoxicillin–clavulanate, ampicillin, ciprofloxacin, cotrimoxazole, fosfomycin, norfloxacin, ofloxacin. *Proteus* spp. and had intermediate sensitivity to cefoxitin and chloramphenicol. *Staphylococcus aureus* bacteria were sensitive to chloramphenicol, oxacillin, and vancomycin and had intermediate sensitivity to amoxicillin, amoxicillin–clavulanate, and cefoxitin.

4. Discussion

4.1. Quantity Profiles of Prophylactic Antibiotics

The assessment of the quantity of antibiotic use was conducted by calculating DDD/100 bed-days based on the classification (Anatomical Therapeutic Chemical Classification) that has been approved worldwide by the World Health Organization (WHO). DDD is defined as the use of antibiotics based on the average daily dose given to 70 kgs adult patients according to main therapeutic indications. However, DDD cannot provide information pertaining to the suitability of the actual daily dose prescription. DDD calculation is influenced by the amount of antibiotic use (grams) and the total length of stay

(bed-days). The higher percentage of antibiotics use leads to the greater the DDD value [15].

The calculation of DDD/100 bed-days between January and June 2019 was divided into pre-, during, and postsurgeries. Overall, the average of prophylactic antibiotic use in pre, during, and postsurgeries in hospital B was higher than in hospital A. Ceftriaxone is the most widely used antibiotic including surgery. Tolbert's 2019 evaluative study on the use of ceftriaxone in tertiary hospitals in Tanzania showed 322 (51.1%) of 630 research samples used ceftriaxone antibiotics. A total of 44 samples (40.7%) received ceftriaxone for surgical prophylaxis purposes that were divided into 32 (72.7%) samples receiving antibiotics before surgery, 3 samples (6.8%) samples receiving ceftriaxone antibiotics during surgery, and 9 samples (20.5%) receiving antibiotics after surgery [16]. Another evaluative study on the use of prophylactic antibiotics in surgical patients at Nekemte Hospital Ethiopia showed that the 153 ceftriaxone samples were the most widely used antibiotics, with a total of 66 samples (43.1%) [17].

Prophylactic antibiotics can significantly reduce the risk of postoperative infections. A meta-analysis of 40 studies testing the effectiveness of ceftriaxone compared with the comparators as the surgical prophylaxis (ampicillin-sulbactam, benzylpenicillin, cefamandole, cefazolin, cefotaxime, cefuroxime) showed that in clean operations, the incidence of SSI in ceftriaxone was 5.14%, and comparator 6.2% (OR -0.22, 95% CI -0.51 to 0.01; $p = 0.047$). In clean-contaminated operations, the incidence of SSI in ceftriaxone was 4.6% and comparator 6.4% (OR -0.36, 95% CI -0.67 to -0.13; $p = 0.001$) [18].

The average value of DDD/100 prophylactic antibiotic bed-days in this study is higher than other studies in one hospital in Indonesia but is still lower than that in the study of the use of prophylactic antibiotics in one hospital in Turkey. The ceftriaxone antibiotics dosage used in hospital B was 87 DDD/100 bed-days, which means there were 87 out of 100 patients who received ceftriaxone 1 DDD antibiotics per day. A primary study of surgical patients in the hospitals in Surabaya assessed the total use of ceftriaxone prophylactic antibiotics using the DDD/100 bed-days unit, and the total use of these antibiotics was 30–54 DDD/100 bed-days [19,20]. These results are still lower when compared with DDD/100 bed-days of this study. However, the total use of prophylactic antibiotics in this study was still lower than that in Turkey, which was 132.4 DDD/100 bed-days, compared with 289.32 DDD/100 bed-days [21].

4.2. Quality Profiles of Prophylactic Antibiotics

According to Permenkes RI RI No. 2406/MENKES/PER/XII/2011 on General Guidelines for the Use of Antibiotics in 2011, the basis for selecting antibiotics should be drawn from the patterns of bacterial sensitivity to antibiotics, the clinical condition of patients, the selection priorities of first-line antibiotics or antibiotics with a narrow spectrum, cost, and adjusted according to the hospital diagnosis and therapy (PDT) Guidelines [11]. The results in this study indicated that of the 487 samples analyzed between January and June 2019, the percentage of compliance with ASHP therapeutic guidelines for the selection of antibiotic types was 18% in hospital A and 2% in hospital B. We postulate that the low accordance in hospital B may be due to the fact that in Indonesia, antibiotics selection depends on the availability of the drugs rather than guideline recommendation.

Based on ASHP therapeutic guidelines, to ensure adequate plasma and tissue concentration during surgery, it is recommended that the drug to be given intravenously within one hour of an incision. In this study, more than 95% of patients received prophylactic antibiotics intravenously, but only around 50% in concordance with the preoperative dosage timing recommendation.

Some antibiotics, such as vancomycin and fluoroquinolones, must be given 120 min before surgery due to the influence of the half-life and protein binding of each antibiotic [22,23]. Allegranzi [7] conducted a meta-analysis of 13 observational studies on 53,975 adult patients to assess the optimal time of administration of surgical prophylactic antibiotics and found that preoperative antibiotics are better than postsurgical drugs to prevent

surgical site infection (SSI) (OR 1.89; 95% CI 1.05–3.4). Administration of antibiotics earlier than 120 min showed a higher prevalence of SSI than the administration of antibiotics within 120 min (OR 5.26; 95% CI 3.29–8.39).

The incidence of SSI in surgery patients in hospital B from January through June 2019 was 2 out of 323 patients (0.62%). The SSI patients in this study both had ceftriaxone at intervals and doses of 2×1 g. The administration time was more than 2 h preincision. Mismatched timing of prophylactic antibiotics can cause SSI and the growth of resistant bacteria. Research conducted by Billoro in 2019 to evaluate the use of prophylactic antibiotics in 255 surgical patients in southern Ethiopia, using a prospective cohort study, showed that administration of surgical prophylactic antibiotics earlier than 1 h before the incision was associated with 20% of SSI cases, whereas administration within 1 h had a lower incidence, at 11.4% ($p = 0.012$). In addition, antibiotic resistance was observed in most types of bacteria in the surgical ward. One of these bacteria, *Escherichia coli*, was resistant to the antibiotics such as ceftriaxone, chloramphenicol, ciprofloxacin, and gentamicin [24].

The selection of the right drug must be accompanied by an accurate dose determination. ASHP guidelines recommend ceftriaxone 2 g, or 50–75 mg/kg body weight, for adults [22,23]. The average body weight of the study sample was >40 kg; thus, the administration of <1 g of ceftriaxone injection was not in accordance with ASHP guidelines [25].

Aside from the timing of the first dose, the dosing interval and duration must be appropriate to achieve minimum effective plasma and tissue concentrations. ASHP recommends a single dose or that the duration of prophylactic antibiotics be <24 h postoperatively [23]. Using the case of more than 1000 beds hospital, Ayele's 2017 evaluative study on the use of ceftriaxone in tertiary hospitals showed that around 70% use of antibiotic prophylaxis for a duration exceeding 7 days [26]. Limiting the duration of prophylactic antibiotics is crucial because the use of antibiotics with a longer duration has the potential to change the normal bacterial flora in the patient's own body and the normal flora in the hospital environment. A disturbed flora can lead to colonization or antimicrobial resistance [25]. The use of prophylactic antibiotics > 24 h carries the risk of increasing the incidence of acute kidney injury and infection by *Clostridium difficile* bacteria [27,28].

4.3. Profile of Surgical Site Infection (SSI)

Extended preoperative waiting times for hospitalized patients increased the risks of SSI. Preoperative waiting time >7 days could increase the risk of SSI 2.48 times greater than preoperative waiting time <7 days (ARR = 2.48 (95% CI 1.28–4.79); $p = 0.007$) [24]. Both our infected patients underwent surgery after undergoing SSI > 7 days inpatient care. They also had a duration of operation > 1 h. Billoro (2019) found patients who underwent surgery >1 h were at risk of experiencing SSI 2.13 times higher than operations of <1 h (ARR = 2.13 (95% CI 1.18–3.86), $p = 0.012$) [24]. Gachabayov [29] found that the incidence of SSI was significantly higher in diabetic patients with hyperglycemia than nondiabetic ones with hyperglycemia (ARR = 2.10 (1.29–3.42, $p = 0.002$)). Our SSI patients were known to have a record of concomitant diabetes mellitus with preoperative blood sugar levels of 149 mg/dL and 138 mg/dL. Patients with blood sugar level that exceeded 100 mg/dL preincision had shown a 1.7 times greater risk of SSI [30].

The strength of this study is its large number of patients ($n > 400$) and follow-up. The reported cases of surgical site infection were not when the patient was in the hospital (inpatient) but during 30–60 days after the day of surgery when they returned to the outpatient clinic. The limitation of this study is that severe cases in ICU and those who died were not accounted for, and there were laboratory limitations, and therefore, the bacteria that cause SSI were not identified.

5. Conclusions

The usage of prophylactic antibiotics for surgical procedures was high and varied between hospitals. The low concordance to antibiotic therapeutic guidelines suggested injudicious antibiotic use. Further surveillance is needed to identify the incidence of antibiotic-resistant bacteria in the future. It is highly recommended that surgeons abide by guideline recommendations, using only a single antibiotic dose for clean surgery. Further intervention and strategies in implementing antibiotic stewardship are needed to improve antibiotic prescribing and its use.

Author Contributions: Conceptualization, R.Y. and F.H.; methodology, F.H.; software, H.W. and K.K.; validation, F.H. and R.Y.; formal analysis, F.H., F.K.M., N.M., and K.K.; investigation, F.K.M., and N.M.; resources, R.Y. and H.W.; data curation, F.K.M. and N.M.; writing—original draft preparation, F.H. and R.Y.; writing—review and editing, K.K., D.S., and R.A.; visualization, N.M.; supervision, D.S. and R.A.; project administration, R.Y. and F.H.; funding acquisition, R.Y. All authors have read and agreed to the published version of the manuscript.

Funding: This study receives funding from the Ministry of Research, Technology, and Higher Education of the Republic of Indonesia No. 015/ST-Lit/LPPM-01/RistekBRIN/Multi/FF/III/2021.

Institutional Review Board Statement: This research received research permission from Husada Utama Hospital Surabaya, Surabaya (hospital A), No.1592/RSHU/Dir./X/2019, and the Regional General Hospital of West Nusa Tenggara Province (hospital B), No. 070/5//03/RSUDP NTB. This study has obtained ethical approval issued by the institutional ethical committee of the University of Surabaya, with the Ethics Agreement No. 109/KE/XI/2019, and the Health Research Ethics Commission of the Regional General Hospital of West Nusa Tenggara Province No. 070.1/13/KEP/2019.

Informed Consent Statement: No informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The authors confirm that the data supporting the findings of this study are available on request.

Acknowledgments: The authors would like to thank the directors and staff of both hospitals for allowing us to conduct research in their hospitals. We would like to thank David Scott, Pharmacy Department, Cardiff University, UK for reviewing, editing, and proofreading the manuscript.

Conflicts of Interest: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.


Ethics Statement: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This research received research permission from Husada Utama Hospital Surabaya (hereafter, hospital A), No.1592/RSHU/Dir./X/2019, and the Regional General Hospital of West Nusa Tenggara Province (hereafter, hospital B), No. 070/5//03/RSUDP NTB. This study obtained ethical approval issued by the institutional ethical committee of the University of Surabaya with the Ethics Agreement No. 109/KE/XI/2019 and the Health Research Ethics Commission of the Regional General Hospital of West Nusa Tenggara Province No. 070.1/13/KEP/2019.

References

1. Yang, X.; Xiao, X.; Wang, L.; Ao, Y.; Song, Y.; Wang, H.; Wang, H. Application of antimicrobial drugs in perioperative surgical incision. *Ann. Clin. Microbiol. Antimicrob.* **2018**, *17*, 2. <https://doi.org/10.1186/s12941-018-0254-0>.
2. Satti, M.Z.; Hamza, M.; Sajid, Z.; Asif, O.; Ahmed, H.; Zaidi, S.M.J.; Irshad, U. Compliance Rate of Surgical Antimicrobial Prophylaxis and its Association with Knowledge of Guidelines Among Surgical Residents in a Tertiary Care Public Hospital of a Developing Country. *Cureus* **2019**, *11*, e4776. <https://doi.org/10.7759/cureus.4776>.
3. Çakmakçi, M. Antibiotic stewardship programmes and the surgeon's role. *J. Hosp. Infect.* **2015**, *89*, 264–246. <https://doi.org/10.1016/j.jhin.2015.01.006>.
4. Hussain, K.; Khan, M.F.; Ambreen, G.; Raza, S.S.; Irfan, S.; Habib, K.; Zafar, H. An antibiotic stewardship program in a surgical ICU of a resource-limited country: Financial impact with improved clinical outcomes. *J. Pharm. Policy Pract.* **2020**, *13*, 69. <https://doi.org/10.1186/s40545-020-00272-w>.
5. National Centre for Antimicrobial Stewardship and Australian Commission on Safety and Quality in Health Care. *Surgical National Antimicrobial Prescribing Survey: Results of the 2016 Pilot*; ACSQHC: Sydney, Australia 2017.

6. WHO. *Global Guidelines for the Prevention of Surgical Site Infection*; 2nd ed.; World Health Organization: Geneva, Switzerland, 2018. Licence: CC BY-NC-SA 3.0 IGO. Available online: <https://apps.who.int/iris/bitstream/handle/10665/250680/9789241549882-eng.pdf?sequence=8> (accessed on 18 June 2021).
7. Allegranzi, B.; Bischoff, P.; de Jonge, S.; Kubilay, N.Z.; Zayed, B.; Gomes, S.M.; Abbas, M.; Atema, J.J.; Gans, S.; van Rijen, M.; et al. New WHO recommendations on preoperative measures for surgical site infection prevention: An evidence-based global perspective. *Lancet Infect. Dis.* **2016**, *16*, e276–e287. [https://doi.org/10.1016/S1473-3099\(16\)30398-X](https://doi.org/10.1016/S1473-3099(16)30398-X).
8. Ling, M.L.; Apisarnthanarak, A.; Abbas, A.; Morikane, K.; Lee, K.Y.; Warriar, A.; Yamada, K. APSIC guidelines for the prevention of surgical site infections. *Antimicrob. Resist. Infect. Control* **2019**, *8*, 174. <https://doi.org/10.1186/s13756-019-0638-8>.
9. WHO. *Global Antimicrobial Resistance Surveillance System (GLASS) Report: Early Implementation 2017–2018*; World Health Organization: Geneva, Switzerland, 2018. Available online: https://www.who.int/docs/default-source/searo/amr/global-antimicrobial-resistance-surveillance-system---glass-report-early-implementation-2017-2018.pdf?sfvrsn=7e629fec_6 (accessed on 18 June 2021).
10. Indonesian Ministry of Health (IMOH). *National Action Plan on Antimicrobial Resistance Indonesia 2017–2019*; Kementerian Kesehatan Republik Indonesia: Jakarta, Indonesia, 2017.
11. Indonesian Ministry of Health (IMOH). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 2406/MENKES/PER/XII/2011 tentang Pedoman Umum Penggunaan Antibiotik*; Direktorat Jenderal Bina Kefarmasian dan Alat–Kesehatan Kementerian Kesehatan Republik Indonesia: Jakarta, Indonesia, 2011. Available online: https://drive.google.com/file/d/1Pu31AVV9ZF0m-InIWyixNwj5mzAt_mkXw/view (accessed on 7 January 2021).
12. Delbridge SIGN 104: Antibiotic Prophylaxis in Surgery. July 2008, Updated April 2014. Available online: <http://www.sign.ac.uk/> (accessed on 24 April 2018).
13. World Health Organization. *Antimicrobial Stewardship Programmes in Health-Care Facilities in Low- and Middle-Income Countries: A WHO Practical Toolkit*; World Health Organization: Geneva, Switzerland, 2019. Available online: <https://apps.who.int/iris/handle/10665/329404> (accessed on 18 June 2021).
14. Nathwani, D.; Varghese, D.; Stephens, J.; Ansari, W.; Martin, S.; Charbonneau, C. Value of hospital antimicrobial stewardship programs [ASPs]: A systematic review. *Antimicrob. Resist. Infect. Control* **2019**, *8*, 35. <https://doi.org/10.1186/s13756-019-0471-0>.
15. Indonesian Ministry of Health (IMOH). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 8 Tahun 2015 tentang Program Pengendalian Resistensi Antimikroba di Rumah Sakit*; Kementerian Kesehatan Republik Indonesia: Jakarta, Indonesia, 2015. Available online: <https://ghsaindonesia.files.wordpress.com/2016/02/peraturan-menteri-kesehatan-ri-no-8-tahun-2015-tentang-pengendalian-resistensi-antimikroba-di-rumah-sakit.pdf> (accessed on 18 June 2021).
16. Sonda, T.B.; Horumpende, P.G.; Kumburu, H.H.; van Zwetselaar, M.; Mshana, S.E.; Alifrangis, M.; Lund, O.; Aarestrup, F.M.; Chilongola, J.O.; Mmbaga, B.T.; et al. Ceftriaxone use in a tertiary care hospital in Kilimanjaro, Tanzania: A need for a hospital antibiotic stewardship programme. *PLoS ONE* **2019**, *14*, e0220261. <https://doi.org/10.1371/journal.pone.0220261>.
17. Alemkere, G. Antibiotic usage in surgical prophylaxis: A prospective observational study in the surgical ward of Nekemte referral hospital. *PLoS ONE* **2018**, *13*, e0203523. <https://doi.org/10.1371/journal.pone.0203523>.
18. Esposito, S.; Noviello, S.; Vanasia, A.; Venturino, P. Ceftriaxone versus other antibiotics for surgical prophylaxis: A meta-analysis. *Clin. Drug Investig.* **2004**, *24*, 29–39. <https://doi.org/10.2165/00044011-200424010-00004>.
19. Pratama, N.Y.I.; Suprapti, B.; Ardiansyah, A.O.; Shinta, D.W. Analisis penggunaan antibiotik pada pasien rawat inap Bedah dengan menggunakan Defined Daily Dose dan Drug Utilization 90% di Rumah Sakit Universitas Airlangga. *J. Farm. Klin. Indones.* **2019**, *8*, 256–63. <https://doi.org/10.15416/ijcp.2019.8.4.256>.
20. Herawati, F.; Yulia, R.; Hak, E.; Hartono, A.H.; Michiels, T.; Woerdenbag, H.J.; Avanti, C. A retrospective surveillance of the antibiotics prophylactic use of surgical procedures in private hospitals in Indonesia. *Hosp. Pharm.* **2019**, *54*, 323–329. <https://doi.org/10.1177/0018578718792804>.
21. Bozkurt, F.; Kaya, S.; Gulsun, S.; Tekin, R.; Deveci, Ö.; Dayan, S.; Hoşoğlu, S. Assessment of perioperative antimicrobial prophylaxis using ATC/DDD methodology. *Int. J. Infect. Dis.* **2013**, *17*, e1212–e1217. <https://doi.org/10.1016/j.ijid.2013.08.003>.
22. Heuer, A.; Kossick, M.A.; Riley, J.; Hewer, I. Update on Guidelines for Perioperative Antibiotic Selection and Administration from the Surgical Care Improvement Project (SCIP) and American Society of Health-System Pharmacists. *AANA J.* **2017**, *85*, 293–299. Available online: [https://www.aana.com/docs/default-source/aana-journal-web-documents-1/update-on-guidelines-for-perioperative-antibiotic-selection-and-administration-from-the-surgical-care-improvement-project-\(scip\)-and-american-society-of-health-system-pharmacists.pdf?sfvrsn=80ad4ab1_4](https://www.aana.com/docs/default-source/aana-journal-web-documents-1/update-on-guidelines-for-perioperative-antibiotic-selection-and-administration-from-the-surgical-care-improvement-project-(scip)-and-american-society-of-health-system-pharmacists.pdf?sfvrsn=80ad4ab1_4) (accessed on 20 June 2021).
23. Bratzler, D.W.; Dellinger, E.P.; Olsen, K.M.; Perl, T.M.; Auwaerter, P.G.; Bolon, M.K.; Fish, D.N.; Napolitano, L.M.; Sawyer, R.G.; Slain, D.; et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am. J. Health Syst. Pharm.* **2013**, *70*, 195–283.
24. Billoro, B.B.; Nunemo, M.H.; Gelan, S.E. Evaluation of antimicrobial prophylaxis use and rate of surgical site infection in surgical ward of Wachemo University Nigist Eleni Mohammed Memorial Hospital, Southern Ethiopia: Prospective cohort study. *BMC Infect. Dis.* **2019**, *19*, 298. <https://doi.org/10.1186/s12879-019-3895-5>.
25. Crader, M.F.; Varacallo, M. *Preoperative Antibiotic Prophylaxis*; StatPearls Publishing: Treasure Island, FL, USA, January 2020. Available online: <https://www.ncbi.nlm.nih.gov/books/NBK442032/> (accessed on 20 June 2021).
26. Ayele, A.A.; Gebresillasse, B.M.; Erku, D.A.; Gebreyohannes, E.A.; Demssie, D.G.; Mersha, A.G.; Tegegn, H.G. Prospective evaluation of ceftriaxone use in medical and emergency wards of Gondar university referral hospital, Ethiopia. *Pharmacol. Res. Perspect.* **2018**, *6*, e00383. <https://doi.org/10.1002/prp2.383>.

27. Srisung, W.; Teerakanok, J.; Tantrachoti, P.; Karukote, A.; Nugent, K. Surgical prophylaxis with gentamicin and acute kidney injury: A systematic review and meta-analysis. *Ann. Transl. Med.* **2017**, *5*, 100. <https://doi.org/10.21037/atm.2017.03.06>.
28. Branch-Elliman, W.; O'Brien, W.; Strymish, J.; Itani, K.; Wyatt, C.; Gupta, K. Association of Duration and Type of Surgical Prophylaxis with Antimicrobial-Associated Adverse Events. *JAMA Surg.* **2019**, *154*, 590–598. <https://doi.org/10.1001/jamasurg.2019.0569>.
29. Gachabayov, M.; Senagore, A.J.; Abbas, S.K.; Yelika, S.B.; You, K.; Bergamaschi, R. Perioperative hyperglycemia: An unmet need within a surgical site infection bundle. *Tech. Coloproctol.* **2018**, *22*, 201–207. <https://doi.org/10.1007/s10151-018-1769-2>.
30. Chiang, H.Y.; Kamath, A.S.; Pottinger, J.M.; Greenlee, J.D.; Howard, M.A., 3rd; Cavanaugh, J.E.; Herwaldt, L.A. Risk factors and outcomes associated with surgical site infections after craniotomy or craniectomy. *J. Neurosurg.* **2014**, *120*, 509–521. <https://doi.org/10.3171/2013.9.JNS13843>



Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cell

Pharmaceuticals

Pharmaceuticals is a peer-reviewed, open access journal of medicinal chemistry and related drug sciences, published monthly online by MDPI. The Swiss Chemical Society (SCS) and Academy of Pharmaceutical Sciences (APS) are partners of *Pharmaceuticals* and their members receive a discount on the article processing charge.

- **Open Access** — free for readers, with article processing charges (APC) paid by authors or their institutions.
- **High Visibility:** Indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and many other databases.
- **Journal Rank:** JCR - Q1 (Pharmacology & Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)
- **Rapid Publication:** manuscripts are peer-reviewed and a first decision provided to authors approximately 13.7 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2021).
- **Recognition of Reviewers:** reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
- **Testimonials:** [see what our authors say about Pharmaceuticals](#)
- **International Electronic Conference on Medicinal Chemistry** (<https://sciforum.net/series/iecmc/latest>)
- **Companion Journal:** *Psychoactives*.

Impact Factor: 5.863 (2020) ; 5-Year Impact Factor: 5.85 (2020)



[Imprint Information](#)



[Journal Flyer](#)



[Open Access](#)

ISSN: 1424-6247

also developed by scimago:



SCIMAGO INSTITUTIONS RANKINGS

SJR

Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name



- Home
- Journal Rankings
- Country Rankings
- Viz Tools
- Help
- About Us

High Purity Reagents
 DSPC, Cholesterol. Customizable lipid synthesis also available. Call us now! broadpharm.com



Pharmaceuticals

COUNTRY

Switzerland

Universities and research institutions in Switzerland

SUBJECT AREA AND CATEGORY

Biochemistry, Genetics and Molecular Biology
Molecular Medicine

Pharmacology, Toxicology and Pharmaceutics
Drug Discovery
Pharmaceutical Science

PUBLISHER

MDPI Multidisciplinary Digital Publishing Institute

H-INDEX

59



Academic Grammar Check

American Journal Experts

PUBLICATION TYPE

Journals

ISSN

14248247

COVERAGE

2009-2020

INFORMATION

[Homepage](#)

[How to publish in this journal](#)

Jean-Jacques.VANDENEYNDE@ex.umons.ac.be



Blibli Official Store

Belanja produk Official Store di Blibli langsung dapat Gratis Ongkir #KarenaKamuNo1

Buka



SCOPE

Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the length of a paper. The multidisciplinary journal welcomes manuscripts covering a wide range of aspects involved in drug discovery and development. The following topics are considered: Small molecules as drug candidates: drug discovery, drug design, medicinal chemistry, combinatorial chemistry, SAR, structure-property correlations, molecular modeling, pharmacophore, and bioinformatics; Biomolecules, natural products, phages, and cells as therapeutic tools: peptides, aptamers, glycans, antibodies, extracts, bacteriophages, and stem cells; Biological targets and biomarkers: enzymes, receptors, membranes, genes, ion channels, inhibitors, agonists, antagonists, neurons, binding affinity, biofilms, bacteria, viruses, parasites, and protein-protein interactions; Radiopharmaceutical sciences, radiochemistry, (hybrid-)imaging, and nuclear medicine: radiopharmaceuticals, radiotracers, fluorescent dye labeled tracers, contrast agents, PET/CT, PET/MRI RMI, SPECT/CT, and scintigraphy; Pharmacokinetics and pharmacodynamics: pharmaceutical analyses, drug effects, ADME, animal experimentation, and clinical trials; Pharmaceutical preparations and drug delivery: dosage form design, bioconjugates, prodrugs, formulation, metabolites, nanomaterials, nanomedicines, and drug targeting.

Join the conversation about this journal



Quartiles

FIND SIMILAR JOURNALS

options

1	2	3	4	5
Current Medicinal Chemistry	Frontiers in Pharmacology	Current Drug Targets	International Journal of Molecular Sciences	Pharmacological Research
ARE	CHE	ARE	CHE	USA
76% similarity	75% similarity	74% similarity	70% similarity	69% similarity





Pharmaceuticals

Q1 Drug Discovery

best quartile

SJR 2020 1.3

powered by scimagojr.com

← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scm
```

SCImago Graphica

Explore, visually communicate and make sense of data with our **new free tool**.

Get it

Metrics based on Scopus® data as of April 2021

K Khyati 1 year ago

Excited to join this

reply

Melanie Ortiz 1 year ago

Dear Kyati, welcome and thanks for your participation! Best Regards, SCImago Team

A All Hussein 2 years ago

Excited to join

reply

P Prakruti Shah 3 years ago

happy reading

reply



Elena Corera · 3 years ago

SCImago Team

Thanks for your participation!

Leave a comment

Name

Email

(will not be published)

I'm not a robot

RECAPTCHA
Privacy - Terms

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2020. Data Source: Scopus®

EST MODUS IN REBUS
© Scimago Lab 2020



Source details

Pharmaceuticals

Open Access ⓘ

Scopus coverage years: from 2009 to Present

Publisher: Multidisciplinary Digital Publishing Institute (MDPI)

ISSN: 1424-8247

Subject area: Pharmacology, Toxicology and Pharmaceutics: Pharmaceutical Science

Pharmacology, Toxicology and Pharmaceutics: Drug Discovery

Biochemistry, Genetics and Molecular Biology: Molecular Medicine

Source type: Journal

CiteScore 2020

4.6 ⓘ

SJR 2020

1.295 ⓘ

SNIP 2020

1.441 ⓘ

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

Improved CiteScore methodology

CiteScore 2020 counts the citations received in 2017-2020 to articles, reviews, conference papers, book chapters and data papers published in 2017-2020, and divides this by the number of publications published in 2017-2020. [Learn more >](#)

CiteScore 2020

$$4.6 = \frac{4,020 \text{ Citations 2017 - 2020}}{882 \text{ Documents 2017 - 2020}}$$

Calculated on 05 May, 2021

CiteScoreTracker 2021 ⓘ

$$3.8 = \frac{6,481 \text{ Citations to date}}{1,711 \text{ Documents to date}}$$

Last updated on 05 October, 2021 • Updated monthly

CiteScore rank 2020 ⓘ

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#53/166	68th
Pharmaceutical Science		
Pharmacology, Toxicology and Pharmaceutics	#65/145	55th
Drug Discovery		

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)

About Scopus

[What is Scopus](#)
[Content coverage](#)
[Scopus blog](#)
[Scopus API](#)
[Privacy matters](#)

Language

[日本語に切り替える](#)
[切换到简体中文](#)
[切换到繁體中文](#)
[Русский язык](#)

Customer Service

[Help](#)
[Contact us](#)

ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗

Copyright © Elsevier B.V. ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

 RELX

Editorial Board

- [Editorial Board](#)
- [Medicinal Chemistry Section](#)
- [Biopharmaceutics Section](#)
- [Natural Products Section](#)
- [Radiopharmaceutical Sciences Section](#)
- [Pharmacology Section](#)
- [Pharmaceutical Technology Section](#)

Editors (15)

Dr. Jean Jacques Vanden Eynde [Website1](#) [Website2](#) [SciProfiles](#)

Editor-In-Chief

Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium

Interests: heterocycles; microwave-induced synthesis; medicinal chemistry; green chemistry

[Special Issues, Collections and Topics in MDPI Journals](#)



Dr. Daniela De Vita [Website](#)

Section Editor-In-Chief

Department of Environmental Biology, Sapienza University of Rome, Rome, Italy

Interests: medicinal plants; phytochemistry; antifungal agents; antiparasitic agents

[Special Issues, Collections and Topics in MDPI Journals](#)



Prof. Dr. Gary J. Stephens [Website](#) [SciProfiles](#)

Section Editor-In-Chief

School of Pharmacy, University of Reading, Whiteknights, PO Box 228, Reading RG6 6AJ, UK

Interests: electrophysiology; voltage-gated calcium channels; cannabinoids; ion channels; GPCRs; pain; ataxia

[Special Issues, Collections and Topics in MDPI Journals](#)



Dr. Alfredo Barzal-Herranz [Website](#) [SciProfiles](#)

Section Editor-In-Chief

Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN-CSIC), PTS Granada,

Av del Conocimiento 17, 18016 Granada, Spain

Interests: structure-function of RNA; aptamers; antisense; ribozymes; viral RNA genomes; RNA as tool; therapeutic RNAs

[Special Issues, Collections and Topics in MDPI Journals](#)



Prof. Dr. Gill Diamond [Website](#) [SciProfiles](#)

Section Editor-In-Chief

Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, Louisville, KY

40292, USA

Interests: regulation of Innate Immunity; antimicrobial peptides; antifungal peptides; defensins; cathelicidins; novel antiviral compounds

[Special Issues, Collections and Topics in MDPI Journals](#)



Prof. Dr. Mary J. Meegan [Website](#) [SciProfiles](#)

Section Editor-In-Chief

School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin,

152–160 Pearse Street, Dublin 2 D02 R590, Ireland

Interests: anticancer drug design; breast cancer; novel antiestrogens; tubulin targeting agents; azetidines, antiestrogen-drug conjugates; estrogen receptor; Burkitt's Lymphoma; Chronic Lymphocytic Leukaemia

[Special Issues, Collections and Topics in MDPI Journals](#)



Prof. Dr. Serge Mordon [Website1](#) [Website2](#) [SciProfiles](#)

Section Editor-In-Chief

INSERM (French National Institute of Health and Medical Research) U1026, The Laboratory of the Bioengineering of

Tissues (BioTis), University of Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux, France

Interests: photodynamic therapy; cancer; clinical evaluation; photosensitizer; dosimetry; Fluorescence; Dosimetry; Fluorescence

[Special Issues, Collections and Topics in MDPI Journals](#)



Prof. Dr. Amélia Pilar Rauter [Website](#)

Section Editor-in-Chief

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Interests: carbohydrate small molecule synthesis; organic and biomolecular chemistry developments towards new therapeutic approaches for diabetes, Alzheimer's disease and other amyloid diseases and carbohydrate-based antibiotics

[Special Issues, Collections and Topics in MDPI Journals](#)



Dr. Irina Velikyan [Website](#) [SciProfiles](#)

Section Editor-in-Chief

Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden

Interests: nuclear medicine; positron emission tomography; molecular imaging; radiopharmaceutical sciences; cancer; diabetes; fibrosis; drug development



Prof. Dr. Thomas Efferth [Website](#) [SciProfiles](#)

Associate Editor

Department of Pharmaceutical Biology, Institute of Pharmacy and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany

Interests: Natural products; Transcriptomics; Network pharmacology; Personalized medicine; Virtual drug screening

[Special Issues, Collections and Topics in MDPI Journals](#)



Prof. Dr. Joachim Jose [Website](#) [SciProfiles](#)

Associate Editor

PharmaCampus Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, Corrensstr. 48, 48149, Muenster, Germany

Interests: autodisplay; assay development and inhibitor testing; whole cell biocatalysts for synthesis of drugs and building blocks; directed evolution of enzyme inhibitors and biocatalysts; biosensor development and diagnostic tools

[Special Issues, Collections and Topics in MDPI Journals](#)



Dr. Klaus Kopka [Website](#) [SciProfiles](#)

Associate Editor

Helmholtz-Zentrum Dresden-Rossendorf (HZDR) e.V., Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany

Interests: radiopharmaceutical sciences; labeling chemistry; medicinal chemistry; PET tracers; radiopharmaceuticals for diagnostics and endoradiotherapy; small molecules; peptides; antibodies and derivatives thereof

[Special Issues, Collections and Topics in MDPI Journals](#)



Dr. Annie Mayence [Website](#) [SciProfiles](#)

Associate Editor

Formerly professor at the Haute Ecole Provinciale de Hainaut-Condorcet, 7330 Saint-Ghislain, Belgium

Interests: medicinal chemistry; organic synthesis; parasitic diseases; orphan drugs

[Special Issues, Collections and Topics in MDPI Journals](#)



Prof. Dr. Maria Emilia de Sousa [Website](#) [SciProfiles](#)

Associate Editor

1. Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências, Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal

2. Interdisciplinar de Investigação Marinha e Ambiental (CIIMAR/CIMAR), Universidade do Porto, Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos, S/N 4450-208 Matosinhos, Portugal

Interests: medicinal chemistry; organic synthesis; heterocycles, P-glycoprotein; anticancer; anticoagulants; chiral drugs; marine natural products

[Special Issues, Collections and Topics in MDPI Journals](#)



Dr. Guangshun Wang [Website](#) [SciProfiles](#)

Associate Editor

Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-5900, USA

Interests: host defense antimicrobial peptides; structural bioinformatics; biomolecular NMR

[Special Issues, Collections and Topics in MDPI Journals](#)



Editorial Board Members (99)

Pharmaceuticals, Volume 14, Issue 11 (November 2021)

– 28 articles

- Issues are regarded as officially published after their release is announced to the [table of contents alert mailing list](#).
- You may [sign up for e-mail alerts](#) to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the 'PDF Full-text' link, and use the free [Adobe Reader](#) to open them.

Order results

Publication Date

Result details

Normal

Show export options

Open Access Review

Opioid Analgesia and Opioid-Induced Adverse Effects: A Review

by Alok K. Paul, Craig M. Smith, Mohammed Rahmatullah, Veeranoot Nissapatorn, Poirat Wlailaitana, Mariana Spetea, Nuri Gueven and Nikolas Dletis

Pharmaceuticals 2021, 14(11), 1091; <https://doi.org/10.3390/ph14111091> (registering DOI) – 27 Oct 2021

Abstract Opioids are widely used as therapeutic agents against moderate to severe acute and chronic pain. Still, these classes of analgesic drugs have many potential limitations as they induce analgesic tolerance, addiction and numerous behavioural adverse effects that often result in patient non-compliance. As [...] [Read more](#).

(This article belongs to the Special Issue [Medicinal Chemistry and Pharmacological Activities of Opioid Drugs](#))

Open Access Systematic Review

Umbilical Cord-Derived Wharton's Jelly for Regenerative Medicine Applications: A Systematic Review

by Benjamin J. Main, Nicola Maffulli, Josiah A. Valk, Hugo C. Rodriguez, Manu Gupta, Saadiq F. El-Amin III and Ashim Gupta

Pharmaceuticals 2021, 14(11), 1090; <https://doi.org/10.3390/ph14111090> (registering DOI) – 27 Oct 2021

Abstract Musculoskeletal ailments affect millions of people around the world and place a high burden on healthcare. Traditional treatment modalities are limited and do not address underlying pathologies. Mesenchymal stem cells (MSCs) have emerged as an exciting therapeutic alternative and Wharton's jelly-derived mesenchymal stem [...] [Read more](#).

(This article belongs to the Special Issue [Drug Screening or Drug Designing Based on Stem Cell Models](#))

Open Access Article

In Vitro Evaluation of a Solid Supersaturated Self Nanoemulsifying Drug Delivery System (Super-SNEDDS) of Aprepitant for Enhanced Solubility

by Hakan Nazli, Burcu Mesut and Yildiz Özsoy

Pharmaceuticals 2021, 14(11), 1089; <https://doi.org/10.3390/ph14111089> (registering DOI) – 27 Oct 2021

Abstract Aprepitant (APR) belongs to Class II of the Biopharmaceutical Classification System (BCS) because of its low aqueous solubility. The objective of the current work is to develop self-nanoemulsifying drug delivery systems (SNEDDS) of APR to enhance its aqueous solubility. Preformulation studies involving screening [...] [Read more](#).

(This article belongs to the Section [Pharmaceutical Technology](#))

Open Access Article

Discordance to ASHP Therapeutic Guidelines Increases the Risk of Surgical Site Infection

by Fauna Herawati, Rika Yulia, Heru Wijono, Firdaus Kabiru Massey, Nurlina Mullani, Kevin Kantono, Diantha Soemantri and Retnosari Andrajati

Pharmaceuticals 2021, 14(11), 1088; <https://doi.org/10.3390/ph14111088> (registering DOI) – 27 Oct 2021

Abstract Clean surgery without contamination does not require prophylactic antibiotics, but there are high-risk surgical procedures that may cause infection and/or involve vital organs such as the heart, brain, and lungs, and these indeed require the use of antibiotics. This study aimed to determine [...] [Read more](#).

(This article belongs to the Section [Pharmacology](#))

Open Access Article



P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)

by Yaogeng Wang, Rolf W. Sparidans, Sander Potters, Rahime Şentürk, Maria C. Lebre, Jos H. Beijnen and Alfred H. Schinkel
Pharmaceuticals 2021, 14(11), 1087; <https://doi.org/10.3390/ph14111087> (registering DOI) - 27 Oct 2021

Abstract Selpercatinib is a targeted, FDA-approved, oral, small-molecule inhibitor for the treatment of rearranged during transfection (RET) proto-oncogene mutation-positive cancer. Using genetically modified mouse models, we investigated the roles of the multidrug efflux transporters ABCB1 and ABCG2, the OATP1A1/B uptake transporters, and the drug-metabolizing [...] [Read more](#).

(This article belongs to the Section Pharmacology)

► [Show Figures](#)

Open Access Article



Design and Microwave Synthesis of New (5Z) 5-Arylidene-2-thioxo-1,3-thiazolidin-4-one and (5Z) 2-Amino-5-arylidene-1,3-thiazol-4(5H)-one as New Inhibitors of Protein Kinase DYRK1A

by Khadidja Bourahla, Solène Guilhéneuf, Emmanuelle Limanton, Ludovic Paquin, Rémy Le Guével, Thierry Charlier, Mustapha Rahmouni, Emilie Durieu, Olivier Lozach, François Carreaux, Laurent Meljor and Jean-Pierre Bazureau

Pharmaceuticals 2021, 14(11), 1086; <https://doi.org/10.3390/ph14111086> (registering DOI) - 27 Oct 2021

Abstract Here, we report on the synthesis of libraries of new 5-arylidene-2-thioxo-1,3-thiazolidin-4-ones **3** (twenty-two compounds) and new 2-amino-5-arylidene-1,3-thiazol-4(5H)-ones **5** (twenty-four compounds) with stereo controlled Z-geometry under microwave irradiation. The 46 designed final compounds were tested in order to determine their activity [...] [Read more](#).

(This article belongs to the Special Issue Heterocyclic Compounds and Their Application in Therapy)

Open Access Article



Pongol Methyl Ether Inhibits Akt and Suppresses Cancer Stem Cell Phenotypes in Lung Cancer Cells

by Arnon Silaech, Satapat Racha, Nithikoon Aksorn, Pennapa Lafay, Sucharat Tungsukruthal, Chanida Vinayanuwattikun, Boonchoo Sritularak and Pithi Chanvorachote

Pharmaceuticals 2021, 14(11), 1085; <https://doi.org/10.3390/ph14111085> (registering DOI) - 26 Oct 2021

Viewed by 181

Abstract Cancer stem cells (CSCs) are an important therapeutic target. The therapeutic agents targeting CSCs should lead to improved clinical outcomes. Here we have demonstrated the CSC-suppressing activity of pongol methyl ether (PME), a pure compound from *Millettia erythrocalyx*. Methods: CSC-suppressing effects were [...] [Read more](#).

(This article belongs to the Special Issue Anticancer Compounds in Medicinal Plants)

► [Show Figures](#)

Open Access Review



Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates

by Joana M. O. Santos, Alexandra C. Costa, Tânia R. Dias, Setareh Safari, Maria Paula Costa e Silva, Rui M. Gil da Costa and Rui Medeiros

Pharmaceuticals 2021, 14(11), 1084; <https://doi.org/10.3390/ph14111084> (registering DOI) - 26 Oct 2021

Viewed by 170

Abstract As a multifactorial and multiorgan syndrome, cancer cachexia is associated with decreased tolerance to antitumor treatments and increased morbidity and mortality rates. The current approaches for the treatment of this syndrome are not always effective and well established. Drug repurposing or repositioning consists [...] [Read more](#).

(This article belongs to the Section Medicinal Chemistry)

► [Show Figures](#)

Open Access Review



Lipid Nanoparticulate Drug Delivery Systems: Recent Advances in the Treatment of Skin Disorders

by Stefan R. Stefanov and Velichka Y. Andonova

Pharmaceuticals 2021, 14(11), 1083; <https://doi.org/10.3390/ph14111083> (registering DOI) - 26 Oct 2021

Viewed by 124

Abstract The multifunctional role of the human skin is well known. It acts as a sensory and immune organ that protects the human body from harmful environmental impacts such as chemical, mechanical, and physical threats, reduces UV radiation effects, prevents moisture loss, and helps [...] [Read more](#).

(This article belongs to the Special Issue Current Insights on Lipid-Based Nanosystems)

► [Show Figures](#)